Clinical Trials Logo

Hepatic Disease clinical trials

View clinical trials related to Hepatic Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT06153394 Not yet recruiting - Thrombosis Clinical Trials

Prolonged Hypercoagulability Following Major Liver Resection for Malignancy

PRIORITY
Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

This clinical trial will investigate the ability of thromboelastrogrpahy (TEG®) to detect hypercoagulability after liver surgery and will examine the effect of extended thromboprophylaxis (medical treatment to prevent the development of blood clots inside blood vessels) in patients undergoing liver surgery for cancer treatment. The liver plays a key role in regulating the process of blood clotting. As a result, blood clots are a major cause of complications and death following liver surgery. This is especially true in cancer patients who are at a higher risk of developing blood clots. Current methods for preventing clotting complications after liver surgery include conventional coagulation blood tests (CCTs) and anticoagulant drugs, such as low molecular weight heparins (LMWHs). Current LMWH treatment is prescribed for one month after surgery, but studies show that the risk of developing blood clots can last up to 3 months. Studies also show that CCTs may not be as effective in detecting clotting issues as more comprehensive testing systems, such as TEG. This study will randomize 50 participants to receive 90 days of thromboprophylaxis (using the LMWH Redesca) or the standard of care 30 days (using the LMWH Fragmin) after liver surgery. The medication will be given by injection, similar to a regular vaccine or an insulin injection. Participants will inject the medication every day, for 30 or 90 days, after surgery. Participants will also have their blood tested for clotting issues via TEG testing before surgery and on post-operative days 1,3,5,30 and 90. After surgery, participants will be monitored by their surgeon for clotting complications and 3 year disease-free survival.

NCT ID: NCT05822635 Recruiting - Pancreatic Diseases Clinical Trials

SpyGlass Surgical Study

Start date: December 1, 2023
Phase:
Study type: Observational

- To document the clinical utility of diagnostic and/or therapeutic intraoperative endoscopy using a thin, single-use, flexible cholangiopancreatoscope - To identify specific surgical procedures in which intraoperative use of a thin, single use, flexible cholangiopancreatoscope suggests clinically meaningful benefit and generate a hypothesis for possible subsequent claims-supportive study

NCT ID: NCT05616442 Not yet recruiting - Hepatic Disease Clinical Trials

Ketotifen in Non-Alcoholic Fatty Liver Disease Patients

Start date: December 1, 2022
Phase: Phase 4
Study type: Interventional

The aim of this study is to investigate the safety and efficacy of using ketotifen in patients with NAFLD patients without cirrhosis

NCT ID: NCT05593211 Completed - Renal Disease Clinical Trials

Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures

Start date: October 17, 2022
Phase: N/A
Study type: Interventional

The primary objective for this study is to assess safety and performance of the Kronos Electrocautery Device for electrocautery procedures following coaxial biopsy procedures on areas that include, but are not limited to, liver, kidney, lungs, breasts, soft tissue, etc.

NCT ID: NCT03767517 Completed - Stroke Clinical Trials

A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders

Start date: August 24, 2020
Phase: N/A
Study type: Interventional

Rural patients with life-limiting illness are at very high risk of not receiving appropriate care due to a lack of health professionals, long distances to treatment centers, and limited palliative care (PC) clinical expertise. Secondly, although culture strongly influences people's response to diagnosis, illness and treatment preferences, culturally-based care models are not currently available for most seriously-ill rural patients and their family caregivers. Lack of sensitivity to cultural differences may compromise PC for minority patients. The purpose of this study is to compare a culturally-based Tele-consult program to usual hospital care to determine whether a culturally-based PC Tele-consult program leads to lower symptom burden in hospitalized African American and White older adults with a life-limiting illness.

NCT ID: NCT03652636 Completed - Hepatic Disease Clinical Trials

Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions

Start date: February 25, 2019
Phase: Phase 4
Study type: Interventional

In patients with hepatic lesions, to evaluate the efficacy of contrast enhanced ultrasound compared to MRI in differentiating focal nodular hyperplasia and hepatic adenoma.

NCT ID: NCT03297073 Recruiting - Hepatic Disease Clinical Trials

Paracetamol Metabolism Research in Postoperative Hepatic Surgery

PARAFOI
Start date: December 20, 2016
Phase: N/A
Study type: Interventional

The main objective of this study was to evaluate the 5-day kinetics of plasma paracetamol levels in postoperative major hepatic surgery (resection greater than or equal to three hepatic segments) compared with less extensive liver resection and hepatic re-intervention. The clearance of indocyanine green is a marker of hepatic perfusion but also of the proper hepatocyte functioning, if hemodynamic conditions are stable. Some patients may be operated on up to four or five times in the liver. Moreover, these patients probably present an increased risk of postoperative hepatocellular insufficiency due to a quantitative and qualitative decrease in their hepatic parenchyma. It is therefore interesting to evaluate the use of paracetamol in this situation.

NCT ID: NCT02104154 Terminated - Hepatic Disease Clinical Trials

Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting

Start date: November 2013
Phase: N/A
Study type: Observational

To establish the performance characteristics of the Samsung LABGEO PT10 by comparing the test results of the PT10 Hepatic assay with results obtained from an FDA-cleared chemistry analyzer.